Plus Therapeutics regains compliance with applicable Nasdaq listing criteria

Plus Therapeutics (PSTV) announced that it received a letter from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 5550(b). Specifically, the Letter confirms that the Company is in compliance with both the Market Value of Listing Securities standard under 5550(b)(2), which requires certain companies to maintain a market value of listed securities of at least $35 million, as well as compliance with the alternative stockholders’ equity threshold under 5550(b)(1), which requires certain companies to maintain stockholders’ equity of at least $2.5 million. Accordingly, the Company now satisfies two alternative criteria under Nasdaq Listing Rule 5550. As a result of such compliance, Nasdaq has permitted the Company the remainder of the previously announced grace period to regain compliance with the $1.00 bid price rule under Nasdaq Listing Rule 5550(a)(2), through November 12, 2025. Nasdaq previously required that the Company remedy the bid price deficiency by September 8, 2025, a deadline that no longer applies.